A Phase 3 interventional study of Bimekizumab and Placebo in Ankylosing Spondylitis, sponsored by UCB Biopharma SRL. Completed at 83 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Spondylitis, Ankylosing by UCB S.A. — none open to participants now, none under way, none of them phase 3. Spondylitis, Ankylosing · UCB S.A..
Among the 11 studies in Spondylitis, Ankylosing by UCB S.A., this one is the only one that started in 2019, is one of 4 in phase 3, and was the 10th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →None of the 11 studies in Spondylitis, Ankylosing by UCB S.A. is open now. The open studies under Spondylitis, Ankylosing, anywhere →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 332 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 303 across the 9 interventional studies, 341 across the 2 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Spondylitis, Ankylosing by UCB S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
Drug: Bimekizumab
Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
Drug: Bimekizumab · Other: Placebo
Subjects will receive bimekizumab at pre-specified time-points.
Also known as: BKZ, UCB4940
Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
Also known as: PBO
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16
ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS), where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA) assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (Bath Ankylosing Spondylitis Functional Index (BASFI)) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.
Time frame: Week 16
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Participants at Week 16
ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.
Time frame: Week 16
Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16
ASAS20 response was defined as relative improvements of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.
Time frame: Week 16
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16
BASDAI is a validated self-reported instrument, which consisted of 6 questions to measure the disease activity of ankylosing spondylitis (AS) from the participant's perspective. It measured the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration). Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0=none to 10= very severe, where higher score indicated high disease activity. A negative value indicated improvement and a positive value indicated worsening.
Time frame: Baseline, Week 16
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16
The Assessment of SpondyloArthritis International Society partial remission was defined as a score of less than or equal to (\<=) 2 units (on a scale of 0-10, where 0=no disease activity and 10=high disease activity) in each of the 4 domains. These 4 domains included: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity).
Time frame: Week 16
Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16
ASDAS-MI is achieved when there is a reduction (improvement) of greater than or equal to (\>=) 2.0 in the Ankylosing Spondylitis Disease Activity Score (ASDAS) relative to Baseline. ASDAS is calculated as the sum of the following components: 1) 0.121 × Total back pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q2 result), 2) 0.058 × Duration of morning stiffness (BASDAI Q6 result), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling (BASDAI Q3 result), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) \[mg/L\] + 1). Total back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 \[no disease activity\] to 10 \[high disease activity\] units). High ASDAS scores mean worse disease. If a participant achieves the ASDAS-MI it indicates a major improvement of their disease.
Time frame: Week 16
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16
The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity), spinal mobility (lateral spinal flexion) and high sensitivity C-reactive protein (hs-CRP)\].
Time frame: Week 16
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16
The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranged from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.
Time frame: Baseline, Week 16
Change From Baseline in Nocturnal Spinal Pain Score Numeric Rating Scale (NRS) at Week 16
Nocturnal spinal pain experienced by ankylosing spondylitis (AS) participants is measured by one question: pain in the spine at night due to AS?. When responding, the participant is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale of 0 (no pain) to 10 (most severe pain) units. A lower score indicates less pain and a negative change represents an improvement.
Time frame: Baseline, Week 16
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16
The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and has shown to be responsive in axial spondyloarthritis (axSpA). Each statement on the ASQoL is given a score of 1=Yes or 0=No. A score of "1" was given where the item was affirmed, indicating adverse quality of life. All item scores were summed to generate the total score ranging from 0 to 18 with a higher score indicating worse health-related quality of life. A negative change from baseline represents an improvement.
Time frame: Baseline, Week 16
Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16
SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range.
Time frame: Baseline, Week 16
Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16
The Bath Ankylosing Spondylitis Disease Metrology Index characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement.
Time frame: Baseline, Week 16
Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16
The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.
Time frame: Baseline, Week 16
Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis Index in the Subgroup of Participants With Enthesitis at Baseline
The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.
Time frame: Baseline, Week 16
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU) period). TEAEs were analyzed and have been reported for Double Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 60 mg Q4W during the study.
Time frame: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study
A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious (Important medical events may include, but are not limited to, potential Hy's Law \[see allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.)
Time frame: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study
TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).
Time frame: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)
The study started to enroll study participants in April 2019 and concluded in August 2022.
| Milestone | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) | Bimekizumab 160 mg Q4W (Week 16 up to Week 52) |
|---|---|---|---|
| Started | 111 | 221 | 0 |
| Completed | 109 | 213 | 0 |
| Not completed | 2 | 8 | 0 |
| Withdrew: Due to covid-19 pandemic and site restrictions | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 2 | 0 |
| Withdrew: Adverse event, serious non-fatal | 0 | 1 | 0 |
| Milestone | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) | Bimekizumab 160 mg Q4W (Week 16 up to Week 52) |
|---|---|---|---|
| Started | 0 | 0 | 319 |
| Completed | 0 | 0 | 298 |
| Not completed | 0 | 0 | 21 |
| Withdrew: Pi decision due to non-compliance and covid 19 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 9 |
| Withdrew: Adverse event, serious non-fatal | 0 | 0 | 2 |
ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS), where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA) assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (Bath Ankylosing Spondylitis Functional Index (BASFI)) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.
| percentage of participants | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16 | 22.5 | 44.8 |
ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.
| percentage of participants | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Participants at Week 16 | 23.4 | 45.7 |
ASAS20 response was defined as relative improvements of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.
| percentage of participants | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16 | 43.2 | 66.1 |
BASDAI is a validated self-reported instrument, which consisted of 6 questions to measure the disease activity of ankylosing spondylitis (AS) from the participant's perspective. It measured the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration). Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0=none to 10= very severe, where higher score indicated high disease activity. A negative value indicated improvement and a positive value indicated worsening.
| scores on a scale | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16 | -1.70 ± 0.21 | -2.74 ± 0.17 |
The Assessment of SpondyloArthritis International Society partial remission was defined as a score of less than or equal to (\<=) 2 units (on a scale of 0-10, where 0=no disease activity and 10=high disease activity) in each of the 4 domains. These 4 domains included: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity).
| percentage of participants | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16 | 7.2 | 24.0 |
ASDAS-MI is achieved when there is a reduction (improvement) of greater than or equal to (\>=) 2.0 in the Ankylosing Spondylitis Disease Activity Score (ASDAS) relative to Baseline. ASDAS is calculated as the sum of the following components: 1) 0.121 × Total back pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q2 result), 2) 0.058 × Duration of morning stiffness (BASDAI Q6 result), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling (BASDAI Q3 result), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) \[mg/L\] + 1). Total back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 \[no disease activity\] to 10 \[high disease activity\] units). High ASDAS scores mean worse disease. If a participant achieves the ASDAS-MI it indicates a major improvement of their disease.
| percentage of participants | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16 | 5.4 | 25.8 |
The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity), spinal mobility (lateral spinal flexion) and high sensitivity C-reactive protein (hs-CRP)\].
| percentage of participants | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16 | 18.9 | 49.3 |
The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranged from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.
| scores on a scale | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16 | -0.95 ± 0.20 | -2.00 ± 0.16 |
Nocturnal spinal pain experienced by ankylosing spondylitis (AS) participants is measured by one question: pain in the spine at night due to AS?. When responding, the participant is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale of 0 (no pain) to 10 (most severe pain) units. A lower score indicates less pain and a negative change represents an improvement.
| scores on a scale | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Change From Baseline in Nocturnal Spinal Pain Score Numeric Rating Scale (NRS) at Week 16 | -1.68 ± 0.25 | -3.16 ± 0.20 |
The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and has shown to be responsive in axial spondyloarthritis (axSpA). Each statement on the ASQoL is given a score of 1=Yes or 0=No. A score of "1" was given where the item was affirmed, indicating adverse quality of life. All item scores were summed to generate the total score ranging from 0 to 18 with a higher score indicating worse health-related quality of life. A negative change from baseline represents an improvement.
| scores on a scale | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16 | -3.07 ± 0.41 | -4.59 ± 0.32 |
SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range.
| T-score | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16 | 5.17 ± 0.82 | 8.54 ± 0.67 |
The Bath Ankylosing Spondylitis Disease Metrology Index characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement.
| scores on a scale | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16 | -0.17 ± 0.09 | -0.45 ± 0.07 |
The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.
| scores on a scale | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16 | -1.04 ± 0.33 | -2.12 ± 0.26 |
The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.
| percentage of participants | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) |
|---|---|---|
| Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis Index in the Subgroup of Participants With Enthesitis at Baseline | 32.8 | 51.5 |
TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU) period). TEAEs were analyzed and have been reported for Double Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 60 mg Q4W during the study.
| percentage of participants | Double Blind Treatment Period (up to Week 16): Placebo | Double Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4W | Maintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4W | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W |
|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | 43.2 | 54.3 | 68.3 | 75.8 |
A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious (Important medical events may include, but are not limited to, potential Hy's Law \[see allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.)
| percentage of participants | Double Blind Treatment Period (up to Week 16): Placebo | Double Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4W | Maintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4W | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W |
|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study | 0.9 | 2.3 | 4.7 | 6.1 |
TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).
| percentage of participants | Double Blind Treatment Period (up to Week 16): Placebo | Double Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4W | Maintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4W | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W |
|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study | 0 | 3.2 | 2.8 | 4.8 |
Collected over From Baseline (Day 1) until Safety-Follow-Up (up to Week 68). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind Treatment Period (up to Week 16): Placebo | 0/111 (0%) | 1/111 (0.9%) | 16/111 (14.4%) |
| Double Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4W | 0/221 (0%) | 5/221 (2.3%) | 43/221 (19.5%) |
| Maintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4W | 0/319 (0%) | 15/319 (4.7%) | 64/319 (20.1%) |
| Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W | 0/330 (0%) | 20/330 (6.1%) | 95/330 (28.8%) |
| Event | Double Blind Treatment Period (up to Week 16): Placebo | Double Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4W | Maintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4W | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W |
|---|---|---|---|---|
| SyncopeNervous system disorders | 0/111 | 0/221 | 4/319 | 4/330 |
| Viral infectionInfections and infestations | 1/111 | 0/221 | 0/319 | 0/330 |
| DepressionPsychiatric disorders | 1/111 | 0/221 | 0/319 | 0/330 |
| GoitreEndocrine disorders | 0/111 | 1/221 | 0/319 | 1/330 |
| Colitis ulcerativeGastrointestinal disorders | 0/111 | 1/221 | 0/319 | 1/330 |
| Crohn's diseaseGastrointestinal disorders | 0/111 | 1/221 | 0/319 | 1/330 |
| CholelithiasisHepatobiliary disorders | 0/111 | 1/221 | 0/319 | 1/330 |
| Hepatitis AInfections and infestations | 0/111 | 1/221 | 0/319 | 1/330 |
| Sinus node dysfunctionCardiac disorders | 0/111 | 0/221 | 1/319 | 1/330 |
| Hiatus herniaGastrointestinal disorders | 0/111 | 0/221 | 1/319 | 1/330 |
| Event | Double Blind Treatment Period (up to Week 16): Placebo | Double Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4W | Maintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4W | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/111 | 17/221 | 17/319 | 30/330 |
| Upper respiratory tract infectionInfections and infestations | 8/111 | 6/221 | 16/319 | 21/330 |
| Oral CandidiasisInfections and infestations | 0/111 | 10/221 | 12/319 | 20/330 |
| DiarrhoeaGastrointestinal disorders | 1/111 | 7/221 | 12/319 | 18/330 |
| HeadacheNervous system disorders | 5/111 | 9/221 | 11/319 | 18/330 |
Baseline Characteristics refer to the Safety Set which consisted of all randomized study participants who received at least one dose of the investigational medicinal product (IMP).
| Age, Categorical(Participants) | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 109 | 212 | 321 |
| >=65 years | 2 | 9 | 11 |
| Age, Continuous(years) | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) | Total |
|---|---|---|---|
| Mean | 39.2 ± 12.6 | 41.0 ± 12.1 | 40.4 ± 12.3 |
| Sex: Female, Male(Participants) | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) | Total |
|---|---|---|---|
| Female | 31 | 61 | 92 |
| Male | 80 | 160 | 240 |
| Race/Ethnicity, Customized(Participants) | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) | Total |
|---|---|---|---|
| Asian | 20 | 37 | 57 |
| Black | 1 | 0 | 1 |
| White | 90 | 177 | 267 |
| Other/Mixed | 0 | 3 | 3 |
| Missing | 0 | 4 | 4 |
| Race/Ethnicity, Customized(Participants) | Placebo (up to Week 16) | Bimekizumab 160 mg Q4W (up to Week 16) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 110 | 218 | 328 |
| Missing | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Apr 2019 to primary completion in Sep 2021, 28 months.
Results were first posted in Oct 2024, 3 years 1 month after primary completion. A results delay was requested in Sep 2022.
Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 28 months is above that.
Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab